Xenon Pharmaceuticals Inc.
Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, A Kv7 potassium channel opener that is …
Biotechnology
CA, Burnaby [HQ]
FA
Fundamental Analysis · Most Recent Quarter
A dedicated fundamental analysis might help you to get a quick overview
of the
financial stability. It is important to understand the
FA Algorithm
and the criterias before valuing it as a top-tier resource.
1
Financial Health
| Metric | Q3 | Q1 | Δ in % | |
|---|---|---|---|---|
| Current Ratio | 48.29 | 31.82 | 21.46 | |
| Debt/Assets | n.A. | n.A. | n.A. | |
| Debt/Equity | n.A. | n.A. | n.A. | |
| Net Debt/EBITDA | -47.86 | 0.83 | 1.59 | |
| Naive Interpretation | member | |||
2
Per Share
| Metric | Q3 | Q1 | Δ in % | |
|---|---|---|---|---|
| Book Value | 18.61 | 11.44 | 9.65 | |
| Cash | 12.99 | 9.02 | 7.98 | |
| Capex | -100.00 | < 0.005 | 0.00 | |
| Free Cash Flow | -100.00 | -0.56 | 0.00 | |
| Revenue | 0.00 | 0.00 | 0.00 | |
| Naive Interpretation | member | |||
3
Profitability
| Metric | Q3 | Q1 | Δ in % | |
|---|---|---|---|---|
| Gross Margin | 0.00 | 0.00 | 0.00 | |
| Operating Margin | 0.00 | 0.00 | 0.00 | |
| ROA | 27.78 | -0.05 | -0.07 | |
| ROE | 29.07 | -0.05 | -0.08 | |
| ROIC | 21.32 | -0.07 | -0.08 | |
| Naive Interpretation | member | |||
4
Valuation
The "Valuation Entry" for the Focus of XENE is permitted for members.
5
Growth
The "Growth Entry" for the Focus of XENE is permitted for members.
6
Leverage & Liquidity